Syril Pettit
Research Subjects
Syril Pettit has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
B. Berridge
1 shared publicationBjoern Riefke
Bayer Schering Pharma AG, D-13342 Berlin, Germany
1 shared publicationBrian Guth
Boehringer Ingelheim, Ingelheim am Rhein, Germany
1 shared publicationDaniela Ennulat
GlaxoSmithKline, King of Prussia, Pennsylvania 19406-0939
1 shared publicationDavid Hoffman
Sanofi-aventis, Bridgewater, New Jersey 08807
1 shared publicationDenise Bounous
Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000
1 shared publication
Latest Publications
- Open Access
- 18 May 2011
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 122 (2) , 235-252
Biological Qualification of Biomarkers of Chemical-Induced Renal Toxicity in Two Strains of Male Rat
This study reports the evaluation of four urinary biomarkers of renal toxicity, α-glutathione-S-transferase (α-GST), μ-GST, clusterin, and renal papillary antigen-1 (RPA-1), in male Sprague-Dawley and Han-Wistar rats given cisplatin, gentamicin, or N-phenylanthranilic acid (NPAA). Kidney injury was diagnosed histopathologically, according to site/nature of renal injury, and graded for severity. The area under the receiver operating characteristic (ROC) curve was used to compare the diagnostic accuracy of each exploratory renal biomarker with traditional indicators of renal function and injury (blood urea nitrogen [BUN], serum creatinine [sCr] as well as urinary N-acetyl-β-D-glucosaminidase [NAG] and protein). These analyses showed that increased urinary α-GST was superior to BUN, sCr, and NAG for diagnosis of proximal tubular (PT) degeneration/necrosis. Paradoxically, urinary α-GST was decreased in the presence of collecting duct (CD) injury without PT injury (NPAA administration). RPA-1 demonstrated high specificity for CD injury, superior to all of the reference biomarkers. The clusterin response correlated well with tubular injury, whatever the location, particularly when regeneration was present (superior to all of the reference markers for cortical tubular regeneration). There was no conclusive evidence for the diagnostic utility of μ-GST. The data were submitted for qualification review by the European Medicines Agency and the US Food and Drug Administration. Both agencies concluded that the data justified the qualification of RPA-1 and increased the level of evidence for, and clarified the context of use of, the previously qualified clusterin for use in male rats. These biomarkers can be used in conjunction with traditional clinical chemistry markers and histopathology in Good Laboratory Practice rodent toxicology studies used to support renal safety studies in clinical trials. Qualification of α-GST must await further explanation of the differences in response to PT and CD injury.
- 18 May 2011
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 122 (2) , 235-252
Open AccessBiological Qualification of Biomarkers of Chemical-Induced Renal Toxicity in Two Strains of Male Rat
This study reports the evaluation of four urinary biomarkers of renal toxicity, α-glutathione-S-transferase (α-GST), μ-GST, clusterin, and renal papillary antigen-1 (RPA-1), in male Sprague-Dawley and Han-Wistar rats given cisplatin, gentamicin, or N-phenylanthranilic acid (NPAA). Kidney injury was diagnosed histopathologically, according to site/nature of renal injury, and graded for severity. The area under the receiver operating characteristic (ROC) curve was used to compare the diagnostic accuracy of each exploratory renal biomarker with traditional indicators of renal function and injury (blood urea nitrogen [BUN], serum creatinine [sCr] as well as urinary N-acetyl-β-D-glucosaminidase [NAG] and protein). These analyses showed that increased urinary α-GST was superior to BUN, sCr, and NAG for diagnosis of proximal tubular (PT) degeneration/necrosis. Paradoxically, urinary α-GST was decreased in the presence of collecting duct (CD) injury without PT injury (NPAA administration). RPA-1 demonstrated high specificity for CD injury, superior to all of the reference biomarkers. The clusterin response correlated well with tubular injury, whatever the location, particularly when regeneration was present (superior to all of the reference markers for cortical tubular regeneration). There was no conclusive evidence for the diagnostic utility of μ-GST. The data were submitted for qualification review by the European Medicines Agency and the US Food and Drug Administration. Both agencies concluded that the data justified the qualification of RPA-1 and increased the level of evidence for, and clarified the context of use of, the previously qualified clusterin for use in male rats. These biomarkers can be used in conjunction with traditional clinical chemistry markers and histopathology in Good Laboratory Practice rodent toxicology studies used to support renal safety studies in clinical trials. Qualification of α-GST must await further explanation of the differences in response to PT and CD injury.
- 28 April 2011
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 30 (3) , 272-286
Cardiovascular Function in Nonclinical Drug Safety Assessment
There are several recent examples where clinically significant, safety-related, drug effects on hemodynamics or cardiac function were not apparent until large clinical trials were completed or the drugs entered the consumer market. Such late-stage safety issues can have significant impact on patient health and consumer confidence, as well as ramifications for the regulatory, pharmaceutical, and financial communities. This manuscript provides recommendations that evolved from a 2009 HESI workshop on the need for improved translation of nonclinical cardiovascular effects to the clinical arena. The authors conclude that expanded and improved efforts to perform sensitive yet specific evaluations of functional cardiovascular parameters in nonclinical studies will allow pharmaceutical companies to identify suspect drugs early in the discovery and development process while allowing promising drugs to proceed into clinical development.
- 28 April 2011
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 30 (3) , 272-286
Cardiovascular Function in Nonclinical Drug Safety Assessment
There are several recent examples where clinically significant, safety-related, drug effects on hemodynamics or cardiac function were not apparent until large clinical trials were completed or the drugs entered the consumer market. Such late-stage safety issues can have significant impact on patient health and consumer confidence, as well as ramifications for the regulatory, pharmaceutical, and financial communities. This manuscript provides recommendations that evolved from a 2009 HESI workshop on the need for improved translation of nonclinical cardiovascular effects to the clinical arena. The authors conclude that expanded and improved efforts to perform sensitive yet specific evaluations of functional cardiovascular parameters in nonclinical studies will allow pharmaceutical companies to identify suspect drugs early in the discovery and development process while allowing promising drugs to proceed into clinical development.
- 1 January 2010
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 61 (1) , 1-2
A call for more integrated cardiovascular safety assessment
- 1 January 2010
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 61 (1) , 1-2
A call for more integrated cardiovascular safety assessment
- Open Access
- 12 June 2008
- Published by Springer Nature in BMC Genomics
- Vol. 9 (1) , 1-16
Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
Background: The use of gene expression profiling in both clinical and laboratory settings would be enhanced by better characterization of variance due to individual, environmental, and technical factors. Meta-analysis of microarray data from untreated or vehicle-treated animals within the control arm of toxicogenomics studies could yield useful information on baseline fluctuations in gene expression, although control animal data has not been available on a scale and in a form best served for data-mining. Results: A dataset of control animal microarray expression data was assembled by a working group of the Health and Environmental Sciences Institute's Technical Committee on the Application of Genomics in Mechanism Based Risk Assessment in order to provide a public resource for assessments of variability in baseline gene expression. Data from over 500 Affymetrix microarrays from control rat liver and kidney were collected from 16 different institutions. Thirty-five biological and technical factors were obtained for each animal, describing a wide range of study characteristics, and a subset were evaluated in detail for their contribution to total variability using multivariate statistical and graphical techniques. Conclusion: The study factors that emerged as key sources of variability included gender, organ section, strain, and fasting state. These and other study factors were identified as key descriptors that should be included in the minimal information about a toxicogenomics study needed for interpretation of results by an independent source. Genes that are the most and least variable, gender-selective, or altered by fasting were also identified and functionally categorized. Better characterization of gene expression variability in control animals will aid in the design of toxicogenomics studies and in the interpretation of their results.
- 12 June 2008
- Published by Springer Nature in BMC Genomics
- Vol. 9 (1) , 1-16
Open AccessSources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories
Background: The use of gene expression profiling in both clinical and laboratory settings would be enhanced by better characterization of variance due to individual, environmental, and technical factors. Meta-analysis of microarray data from untreated or vehicle-treated animals within the control arm of toxicogenomics studies could yield useful information on baseline fluctuations in gene expression, although control animal data has not been available on a scale and in a form best served for data-mining. Results: A dataset of control animal microarray expression data was assembled by a working group of the Health and Environmental Sciences Institute's Technical Committee on the Application of Genomics in Mechanism Based Risk Assessment in order to provide a public resource for assessments of variability in baseline gene expression. Data from over 500 Affymetrix microarrays from control rat liver and kidney were collected from 16 different institutions. Thirty-five biological and technical factors were obtained for each animal, describing a wide range of study characteristics, and a subset were evaluated in detail for their contribution to total variability using multivariate statistical and graphical techniques. Conclusion: The study factors that emerged as key sources of variability included gender, organ section, strain, and fasting state. These and other study factors were identified as key descriptors that should be included in the minimal information about a toxicogenomics study needed for interpretation of results by an independent source. Genes that are the most and least variable, gender-selective, or altered by fasting were also identified and functionally categorized. Better characterization of gene expression variability in control animals will aid in the design of toxicogenomics studies and in the interpretation of their results.
- Open Access
- 1 August 2004
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 112 (12) , A662
Guest Editorial: Toxicogenomics in Risk Assessment: Communicating the Challenges
- 1 August 2004
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 112 (12) , A662
Open AccessGuest Editorial: Toxicogenomics in Risk Assessment: Communicating the Challenges
- Open Access
- 1 January 2001
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 29 (1_suppl) , 191-195
Panel Discussion on the Application of Alternative Models to Cancer Risk Assessment
The International Life Sciences Institute Alternative Carcinogenicity Testing (ILSI ACT) Workshopconcluded with a panel discussion that addressed the framework issue of the appropriate application of alternative models to human cancer risk assessment. This discussion encompassed both technical issues relating to the level of understanding of these models and their output as well as issues relating to the regulatory acceptance of these data. Although there were many different perspectives represented by the panelists, there was also significant consensus on many broad issues. This article focuses on several key areas of emphasis that were addressed by panelists and are considered critical issues for future discussions and evaluations.
- 1 January 2001
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 29 (1_suppl) , 191-195
Open AccessPanel Discussion on the Application of Alternative Models to Cancer Risk Assessment
The International Life Sciences Institute Alternative Carcinogenicity Testing (ILSI ACT) Workshopconcluded with a panel discussion that addressed the framework issue of the appropriate application of alternative models to human cancer risk assessment. This discussion encompassed both technical issues relating to the level of understanding of these models and their output as well as issues relating to the regulatory acceptance of these data. Although there were many different perspectives represented by the panelists, there was also significant consensus on many broad issues. This article focuses on several key areas of emphasis that were addressed by panelists and are considered critical issues for future discussions and evaluations.
- Open Access
- 1 January 2001
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 29 (1_suppl) , 196-197
Epilogue
- 1 January 2001
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 29 (1_suppl) , 196-197
Open AccessEpilogue